Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer
ConclusionDue to the substantial overlap, the HER2 gene expression is unable to properly distinguish HER2-low and HER2-zero IHC whose accurate identification is critical in the context of HER2-negative BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis
ConclusionsEvidence in the setting of predictive tests for extended endocrine therapy is sparse. Most relevant studies investigated the use of BCI, but these study populations were largely restricted to a single age, race, and ethnicity group. Future studies should evaluate a variety of biomarkers in diverse populations. Without sufficient evidence, physicians and patients face a difficult decision in balancing the benefits and risks of endocrine therapy extension. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

A new methodology to predict the oncotype scores based on clinico-pathological data with similar tumor profiles
ConclusionThe proposed methodology makes it possible to predict the distribution of the ODX score for a patient. This prediction is reinforced by the determination of a family of known patients with follow-up of identical scores. The use of this methodology with the pathologist ’s expertise on the different histological and immunohistochemical characteristics has a clinical impact to help oncologist in decision-making regarding breast cancer therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

European quality indicators developed by the European Commission Initiative on Breast Cancer: a first nationwide assessment for the Dutch setting
ConclusionData from the NCR could be used for the calculation of more than 92% of the ECIBC indicators. The quality of breast cancer care in the Netherlands is high, as more than half of the QIs already score above the norm and medium hospital variation was observed. The QIC can be easy and reliably applied. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy
ConclusionHER2  + and ER−/HER2− tumor subtypes showed clear correlation and agreement between preoperative MRI and postoperative pathological assessment of tumor size. This suggests that MRI evaluation could be a suitable predictor to guide the surgical approach. Conversely, correlation and agreement for E R + /HER2− and lobular tumors was poor, evidenced by a difference in tumor size of up to 5 cm. Hence, we demonstrate that histological tumor subtype should be taken into account when planning breast conserving surgery after NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Association of physical weight statuses defined by body mass index (BMI) with molecular subtypes of premenopausal breast cancer: a systematic review and meta-analysis
ConclusionIn the premenopausal breast cancer population, the distribution of patients ’ numbers with different weight statuses was significantly distinct among the various breast cancer subtypes. Additionally, the associations between physical weight statuses and the risk of premenopausal breast cancer subtypes are divergent. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
ConclusionThe combination of metronomic CM with bevacizumab significantly improved PFS over CM alone, although there was no significant difference in OS. Oral metronomic chemotherapy alone has limited activity in advanced breast cancer.ClinicalTrials.gov Identifier: NCT00083031.Date of Registration: May 17, 2004. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients
ConclusionAlthough SBCs are generally associated with a favorable prognosis, our work exhibited that the clinicopathological features of SBC were partly different from former understandings, indicating that therapeutic procedure should be prudent. Further studies are necessary to fully identify the clinical behavior and predictive markers to improve  diagnosis and management in this unique subtype of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Percutaneous and intravenous contrast material injection in contrast-enhanced ultrasound for sentinel lymph node evaluation in patients with breast cancer: importance of discussing difference in purposes
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

“Enhancing survival outcomes through breast-conserving therapy in ipsilateral breast tumor recurrence: insights into metastasis and treatment strategies”
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Interleukin-6 and C-Reactive protein in metastatic breast cancer patients treated with eribulin
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 23, 2024 Category: Cancer & Oncology Source Type: research

Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study
ConclusionDPS showed high accuracy and predictive performance, was able to stratify patients into low or high-risk, and considering its cost and rapidity, has the potential to offer clinical utility. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 20, 2024 Category: Cancer & Oncology Source Type: research

The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and  6 inhibitors: a systematic review and meta-analysis
ConclusionThe available evidence demonstrates a significantly higher risk of progression or death with CDK 4/6 inhibitors in HER2-low tumors. Further research is needed to improve outcomes in patients with HR+-HER2-low tumors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 19, 2024 Category: Cancer & Oncology Source Type: research

Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer
ConclusionTiming of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 19, 2024 Category: Cancer & Oncology Source Type: research

Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial
ConclusionsA subgroup of patients who received STRIDE exhibited improvements in AET adherence. The interrelatedness of moderators suggests an underlying profile of patients with lower symptom burden who benefitted most from the intervention.Study registrationNCT03837496. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 17, 2024 Category: Cancer & Oncology Source Type: research